CLASS II Device recall · Reported 30 Dec 2020 · FDA Enforcement Report

CryoPatch SG Pulmonary Human Cardiac Patch recalled by CryoLife

CryoLife is recalling CryoPatch SG Pulmonary Human Cardiac Patch, distributed nationwide in the US. The recall was initiated on 10 Nov 2020 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesModel/Catalog Number: SGP020 Serial Numbers: 11677186, 11679112, and 11681763 UDI: 00877234000485
Quantity recalled2 units

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

Recall details

Recall number
Z-0653-2021
FDA event ID
86890
Recalling firm
CryoLife, Kennesaw, GA
Classification
Class II
Status
Terminated
Recall initiated
10 Nov 2020
FDA classified
21 Dec 2020
Reported
30 Dec 2020
Type
Voluntary: Firm initiated
Customers notified by
Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit
Reason category
Device Malfunction

Timeline

10 Nov 2020Recall initiated by company
21 Dec 2020Classified by FDA+41 days
30 Dec 2020Published in enforcement report+9 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

On November 10, 2020, it was discovered that there are post- processing microbial culture test failures for other allografts, processed using a TRIS saline solution lot that was also used in processing allografts subjected to the recall.

Device recalls are issued when a component, software or design fault could cause the device to fail or give wrong readings. Many are corrections applied in the field rather than physical returns.

Product as listed by the FDA

CryoPatch SG Pulmonary Human Cardiac Patch. The patch is cryopreserved in a tissue culture medium containing cryoprotectants within the innermost pouch of a three-pouch packaging system. The packaging system not only withstands ultracold temperatures, but also allows for aseptic introduction of the patch into the operating environment. Supercooling by liquid nitrogen boost is begun prior to crystallization to minimize ice crystal damage to the patch matrix. Finally, the patch is transferred for long-term storage at or below 135¿ C. CryoPatch SG is distributed in three anatomic configurations: pulmonary hemi-artery, pulmonary trunk and pulmonary branch.

Where it was distributed

Distributed nationwide to GA, AZ, TX, MO, and OK.

Nationwide ArizonaGeorgiaMissouriOklahomaTexas

Questions about this recall

Why was it recalled?

On November 10, 2020, it was discovered that there are post- processing microbial culture test failures for other allografts, processed using a TRIS saline solution lot that was also used in processing allografts subjected to the recall.

Which lots are affected?

Model/Catalog Number: SGP020 Serial Numbers: 11677186, 11679112, and 11681763 UDI: 00877234000485

Where was it sold?

Distributed nationwide to GA, AZ, TX, MO, and OK.

What should I do if I have it?

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

Other products in this recall event

1 other product · FDA event 86890

This product is part of a recall event; the main page for the event is CryoValve SG Pulmonary Human Heart Valve recalled by CryoLife.

ReportedClassRecallCompanyReasonWhere
CLASS IICryoValve SG Pulmonary Human Heart Valve recalled by CryoLifeCryoLifeDevice MalfunctionNationwide

More recalls from CryoLife

All 14

Other Other Medical Devices recalls

All 13,908